Shots:
Alectos to receive $15M for an exclusive global license to AL01811 & additional unnamed backup molecules & is eligible to receive ~$77.5M in development milestones & $630M in commercial milestones along with royalties
Additionally, both companies will work on preclinical activities for AL01811 (selective GBA2 inhibitor). Biogen will be responsible for all development, regulatory, manufacturing, and commercial activities and costs of the product after AL01811 is advanced to the clinic
The collaboration will combine Alectos’ expertise in small-molecule therapeutics with Biogen’s development capabilities in movement disorders to develop AL01811 for patients with PD
Ref: Globenewswire| Image: Biogen
